296 related articles for article (PubMed ID: 35568026)
21. Mechanism for Synthetic Lethality in BRCA-Deficient Cancers: No Longer Lagging Behind.
van Wietmarschen N; Nussenzweig A
Mol Cell; 2018 Sep; 71(6):877-878. PubMed ID: 30241603
[TBL] [Abstract][Full Text] [Related]
22. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
23. PARP inhibitors: Synthetic lethality in the clinic.
Lord CJ; Ashworth A
Science; 2017 Mar; 355(6330):1152-1158. PubMed ID: 28302823
[TBL] [Abstract][Full Text] [Related]
24. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
25. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic Application of PARP Inhibitors in Neuro-Oncology.
Ning J; Wakimoto H
Trends Cancer; 2020 Feb; 6(2):147-159. PubMed ID: 32061304
[TBL] [Abstract][Full Text] [Related]
27. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.
Lee JM; Ledermann JA; Kohn EC
Ann Oncol; 2014 Jan; 25(1):32-40. PubMed ID: 24225019
[TBL] [Abstract][Full Text] [Related]
28. Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells.
Sullivan-Reed K; Bolton-Gillespie E; Dasgupta Y; Langer S; Siciliano M; Nieborowska-Skorska M; Hanamshet K; Belyaeva EA; Bernhardy AJ; Lee J; Moore M; Zhao H; Valent P; Matlawska-Wasowska K; Müschen M; Bhatia S; Bhatia R; Johnson N; Wasik MA; Mazin AV; Skorski T
Cell Rep; 2018 Jun; 23(11):3127-3136. PubMed ID: 29898385
[TBL] [Abstract][Full Text] [Related]
29. Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.
Kyle S; Thomas HD; Mitchell J; Curtin NJ
Br J Radiol; 2008 Oct; 81 Spec No 1():S6-11. PubMed ID: 18820000
[TBL] [Abstract][Full Text] [Related]
30. BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality.
Murai J; Pommier Y
Cancer Res; 2023 Apr; 83(8):1173-1174. PubMed ID: 37057596
[TBL] [Abstract][Full Text] [Related]
31. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
32. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.
Dedes KJ; Wilkerson PM; Wetterskog D; Weigelt B; Ashworth A; Reis-Filho JS
Cell Cycle; 2011 Apr; 10(8):1192-9. PubMed ID: 21487248
[TBL] [Abstract][Full Text] [Related]
33. Replication Gaps Underlie BRCA Deficiency and Therapy Response.
Panzarino NJ; Krais JJ; Cong K; Peng M; Mosqueda M; Nayak SU; Bond SM; Calvo JA; Doshi MB; Bere M; Ou J; Deng B; Zhu LJ; Johnson N; Cantor SB
Cancer Res; 2021 Mar; 81(5):1388-1397. PubMed ID: 33184108
[TBL] [Abstract][Full Text] [Related]
34. Resurrection of PARP Inhibitors in Breast Cancer.
Lyons TG; Robson ME
J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424
[TBL] [Abstract][Full Text] [Related]
35. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
36. PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells.
Noordermeer SM; van Attikum H
Trends Cell Biol; 2019 Oct; 29(10):820-834. PubMed ID: 31421928
[TBL] [Abstract][Full Text] [Related]
37. PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?
Lightfoot M; Montemorano L; Bixel K
Curr Oncol Rep; 2020 Feb; 22(3):29. PubMed ID: 32067102
[TBL] [Abstract][Full Text] [Related]
38. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
39. Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors.
Bhin J; Paes Dias M; Gogola E; Rolfs F; Piersma SR; de Bruijn R; de Ruiter JR; van den Broek B; Duarte AA; Sol W; van der Heijden I; Andronikou C; Kaiponen TS; Bakker L; Lieftink C; Morris B; Beijersbergen RL; van de Ven M; Jimenez CR; Wessels LFA; Rottenberg S; Jonkers J
Cell Rep; 2023 May; 42(5):112538. PubMed ID: 37209095
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the methods to identify patients who may benefit from PARP inhibitor use.
Lim D; Ngeow J
Endocr Relat Cancer; 2016 Jun; 23(6):R267-85. PubMed ID: 27226207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
